Anti-diabetic effects of luteolin and luteolin-7-O-glucoside on KK-Ay mice

Bioscience, Biotechnology and Biochemistry

Volumn 80, Issue 8, 2016, Pages 1580-1586

  Zang, Yanqing ^a,b   Igarashi, Kiharu ^c   Li, Yu Li ^a  

^a JILIN AGRICULTURAL UNIVERSITY   (China)

^b HEILONGJIANG BAYI AGRICULTURAL UNIVERSITY   (China)

^c YAMAGATA UNIVERSITY   (Japan)

Author keywords

Diabetes; Kk ay mice; Luteolin; Luteolin 7 O glucoside

Indexed keywords

CARBOHYDRATES; GENE EXPRESSION; MAMMALS; MEDICAL PROBLEMS;

ANTI DIABETICS; ANTI-INFLAMMATORIES; BLOOD GLUCOSE; KK-AY MICE; LIPID SYNTHESIS; LUTEOLIN; LUTEOLIN-7-O-GLUCOSIDE; MRNA EXPRESSION;

FLAVONOIDS;

ANTIDIABETIC AGENT; FLAVONE DERIVATIVE; GLUCOSE BLOOD LEVEL; GLUCOSIDE; INSULIN; LUTEOLIN; LUTEOLIN-7-O-GLUCOSIDE;

ADVERSE EFFECTS; ANIMAL; BLOOD; CARBOHYDRATE LOADING DIET; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; LIPID METABOLISM; LIVER; MALE; METABOLISM; MOUSE; PATHOLOGY; TRANSGENIC MOUSE;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIET, CARBOHYDRATE LOADING; FLAVONES; GLUCOSIDES; HYPOGLYCEMIC AGENTS; INSULIN; LIPID METABOLISM; LIVER; LUTEOLIN; MALE; MICE; MICE, TRANSGENIC;

EID: 84979085439     PISSN: 09168451     EISSN: 13476947     Source Type: Journal    
DOI: 10.1080/09168451.2015.1116928     Document Type: Article

References (37)

1. Asif M. The prevention and control the type-2 diabetes by changing lifestyle and dietary pattern. J. Educ. Health Promot. 2014;3:1-8.
2. Riobo Servan P. Obesity and diabetes. Nutr. Hosp. 2013;28 Suppl 5:138-143.
3. Xiao J, Chen T, Cao H. Flavonoid glycosylation and biological benefits. Biotechnol. Adv. 2014. doi:10.1016/j.biotechadv.2014.05.004.
4. Seelinger G, Merfort I, Schempp CM. Anti-oxidant, anti-inflammatory and anti-allergic activities of luteolin. Planta Med. 2008;74:1667-1677.
5. Xu N, Zhang L, Dong J, et al. Low-dose diet supplement of a natural flavonoid, luteolin, ameliorates diet-induced obesity and insulin resistance in mice. Mol. Nutr. Food Res. 2014;58:1258-1268.
6. Kwon E, Jung UJ, Park T, et al. Luteolin attenuates hepatic steatosis and insulin resistance through the interplay between the liver and adipose tissue in diet-induced obese mic. Diabetes. 2014;64:1658-1669.
7. Schutz K, Kammerer DR, Carle R, et al. Characterization of phenolic acids and flavonoids in dandelion (Taraxacum officinale WEB. ex WIGG.) root and herb by high-performance liquid chromatography/electrospray ionization mass spectrometry. Rapid Commun. Mass Spectrom. 2005;19:179-186.
8. Park CM, Song YS. Luteolin and luteolin-7-O-glucoside inhibit lipopolysaccharide-induced inflammatory responses through modulation of NF-êB/AP-1/PI3K-Akt signaling cascades in RAW 264.7 cells. Nutr. Res. Pract. 2013;7:423-429.
9. Hu C, Kitts DD. Luteolin and luteolin-7-O-glucoside from dandelion flower suppress iNOS and COX-2 in RAW264.7 cells. Mol. Cell Biochem. 2004;265:107-113.
10. Folch J, Lebaron FN. The isolation from brain tissue of a trypsin-resistant protein fraction containing combined inositol, and its relation to neurokeratin. J. Neurochem. 1956;1:101-108.
11. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.
12. Mihara M, Uchiyama M. Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. Anal. Biochem. 1978;86:271-278.
13. Kumar S, Korsey JA, Muesing RA, et al. Comparative studies of the pigeon liver fatty acid synthetase complex and its subunits. J. Biol. Chem. 1970;245:4732-4744.
14. Carey E, Dils R. Fatty acid biosynthesis. V. Purification and characterisation of fatty acid synthetase from lactating-rabbit mammary gland. Bilchim. Biophys. Acta. 1970;210:371-387.
15. Kelley DS, Nelson GJ, Hunt JE. Effect of prior nutritional status on the activity of lipogenic enzymes in primary monolayer cultures of rat hepatocytes. Biochem. J. 1986;235:87-90.
16. Sasaki Y, Suzuki W, Shimada T, et al. Dose dependent development of diabetes mellitus and non-alcoholic steatohepatitis in monosodium glutamate-induced obese mice. Life Sci. 2009;85:490-498.
17. Liu Y, Fu X, Lan N, et al. Luteolin protects against high fat diet-induced cognitive deficits in obesity mice. Behav. Brain Res. 2014;267:178-188.
18. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J. Clin. Invest. 2006;116:1793-1801.
19. Agrawal NK, Kant S. Targeting inflammation in diabetes: newer therapeutic options. World J. Diabetes. 2014;5:697-710.
20. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993;259:87-91.
21. Deqiu Z, Kang L, Jiali Y, et al. Luteolin inhibits inflammatory response and improves insulin sensitivity in the endothelium. Biochimie. 2011;93:506-512.
22. Ghorbani M, Shafiee Ardestani M, Gigloo SH, et al. Anti diabetic effect of CL 316,243 (a beta3-adrenergic agonist) by down regulation of tumour necrosis factor (TNF-alpha) expression. PLoS One. 2012;7:e45874.
23. Imoto K, Kukidome D, Nishikawa T, et al. Impact of mitochondrial reactive oxygen species and apoptosis signal-regulating kinase 1 on insulin signaling. Diabetes. 2006;55:1197-1204.
24. Mehrotra S, Ling KL, Bekele Y, et al. Lipid hydroperoxide and markers of renal disease susceptibility in African-Caribbean and Caucasian patients with Type 2 diabetes mellitus. Diabet. Med. 2001;18:109-115.
25. Savu O, Ionescu-Tirgoviste C, Atanasiu V, et al. Increase in total antioxidant capacity of plasma despite high levels of oxidative stress in uncomplicated type 2 diabetes mellitus. J. Int. Med. Res. 2012;40:709-716.
26. Harte RA, Kirk EA, Rosenfeld ME, et al. Initiation of hyperinsulinemia and hyperleptinemia is diet dependent in C57BL/6 Mice. Horm. Metab. Res. 1999;31:570-575.
27. El-Bassossy HM, Abo-Warda SM, Fahmy A. Chrysin and luteolin attenuate diabetes-induced impairment in endothelialdependent relaxation: effect on lipid profile, AGEs and No generation. Phytother. Res. 2013;27:1678-1684.
28. Ikarashi N, Toda T, Okaniwa T, et al. Anti-Obesity and antidiabetic effects of acacia polyphenol in obese diabetic KKAy mice fed high-fat diet. Evid. Based Complement. Alternat. Med. 2011;2011:1-10.
29. Yap F, Craddock L, Yang J. Mechanism of AMPK suppression of LXR-dependent Srebp-1c transcription. Int. J. Biol. Sci. 2011;7:645-650.
30. Sa C, Oliveira AR, Machado C, et al. Effects on liver lipid metabolism of the naturally occurring dietary flavone luteolin-7-glucoside. Evid. Based Complement Alternat. Med. 2015. doi:10.1155/2015/647832.
31. Liu G, Zhang Y, Liu C, et al. Luteolin alleviates alcoholic liver disease induced by chronic and binge ethanol feeding in mice. J. Nutr. 2014;144:1009-1015.
32. Murota K, Shimizu S, Miyamoto S, et al. Unique uptake and transport of isoflavone aglycones by human intestinal caco-2 cells: comparison of isoflavonoids and flavonoids. J. Nutr. 2002;132:1956-1961.
33. Izumi T, Piskula MK, Osawa S, et al. Soy isoflavone aglycones are absorbed faster and in higher amounts than their glucosides in humans. J. Nutr. 2000;130:1695-1699.
34. Wiczkowski W, Romaszko J, Bucinski A, et al. Quercetin from shallots (Allium cepa L. var. aggregatum) is more bioavailable than its glucosides. J. Nutr. 2008;138:885-888.
35. Song YS, Park CM. Luteolin and luteolin-7-O-glucoside strengthen antioxidative potential through the modulation of Nrf2/MAPK mediated HO-1 signaling cascade in RAW 264.7 cells. Food Chem. Toxicol. 2014;65:70-75.
36. Shimoi K, Okada H, Furugori M, et al. Intestinal absorption of luteolin and luteolin 7-O-β-glucoside in rats and humans. FEBS. Lett. 1998;438:220-224.
37. Kim JS, Kwon CS, Son KH. Inhibition of alpha-glucosidase and amylase by luteolin, a flavonoid. Biosci. Biotechnol. Biochem. 2000;64:2458-2461.